Biotech | May 19, 2022
Piramal Pharma Solutions new API plant in Canada goes online
It is part of the company's CAD $30 million capital investment in the Aurora, Canada site
It is part of the company's CAD $30 million capital investment in the Aurora, Canada site
Bempedoic Acid administered as a 180-mg dose, is approved by the USFDA and European Union for the treatment of hypercholesterolemia
Children 5 through 11 years of age are now authorized to receive a booster dose at least five months after the second dose of the two-dose primary series
The drug will be available in 600 hospitals and 105 DTPs
Adynovate in combination with Mypkfit offers personalized treatment and enables HCPs and patients to monitor factor levels from home and help achieve optimum QOL outcomes
Tirzepatide is primarily indicated for the treatment of T2D and is expected to receive its decision from the FDA in Q2 2022
The treatment of chorea associated with HD is within the scope of this Orphan Drug Designation
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
Anand Rathi maintains long-term guidance of 10-15% revenue growth and 40% EBITDA margins
ASC22 (Envafolimab) is a subcutaneously administered single-domain antibody against PD-L1 and has the potential to restore virus-specific immune responses in patients with chronic viral infection
Subscribe To Our Newsletter & Stay Updated
